PPH vs. XBI
Compare and contrast key facts about VanEck Vectors Pharmaceutical ETF (PPH) and SPDR S&P Biotech ETF (XBI).
PPH and XBI are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. PPH is a passively managed fund by VanEck that tracks the performance of the MVIS US Listed Pharmaceutical 25 Index. It was launched on Dec 20, 2011. XBI is a passively managed fund by State Street that tracks the performance of the S&P Biotechnology Select Industry Index. It was launched on Feb 6, 2006. Both PPH and XBI are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.
Performance
PPH vs. XBI - Performance Comparison
Loading graphics...
PPH vs. XBI - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
PPH VanEck Vectors Pharmaceutical ETF | 2.25% | 22.00% | 8.05% | 6.95% | 2.64% | 17.79% | 5.49% | 19.39% | -5.89% | 15.23% |
XBI SPDR S&P Biotech ETF | 5.43% | 35.89% | 1.01% | 7.60% | -25.87% | -20.45% | 48.33% | 32.56% | -15.28% | 43.77% |
Returns By Period
In the year-to-date period, PPH achieves a 2.25% return, which is significantly lower than XBI's 5.43% return. Over the past 10 years, PPH has underperformed XBI with an annualized return of 8.21%, while XBI has yielded a comparatively higher 9.39% annualized return.
PPH
- 1D
- 1.55%
- 1M
- -4.34%
- YTD
- 2.25%
- 6M
- 12.24%
- 1Y
- 20.59%
- 3Y*
- 13.02%
- 5Y*
- 10.93%
- 10Y*
- 8.21%
XBI
- 1D
- 0.64%
- 1M
- 1.58%
- YTD
- 5.43%
- 6M
- 27.21%
- 1Y
- 65.07%
- 3Y*
- 19.25%
- 5Y*
- -1.16%
- 10Y*
- 9.39%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
PPH vs. XBI - Expense Ratio Comparison
PPH has a 0.36% expense ratio, which is higher than XBI's 0.35% expense ratio.
Return for Risk
PPH vs. XBI — Risk / Return Rank
PPH
XBI
PPH vs. XBI - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for VanEck Vectors Pharmaceutical ETF (PPH) and SPDR S&P Biotech ETF (XBI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| PPH | XBI | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.06 | 2.28 | -1.22 |
Sortino ratioReturn per unit of downside risk | 1.55 | 2.99 | -1.44 |
Omega ratioGain probability vs. loss probability | 1.20 | 1.38 | -0.18 |
Calmar ratioReturn relative to maximum drawdown | 1.81 | 4.41 | -2.61 |
Martin ratioReturn relative to average drawdown | 4.66 | 16.21 | -11.55 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| PPH | XBI | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.06 | 2.28 | -1.22 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.74 | -0.04 | +0.78 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.49 | 0.29 | +0.19 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.31 | 0.36 | -0.05 |
Correlation
The correlation between PPH and XBI is 0.59, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Dividends
PPH vs. XBI - Dividend Comparison
PPH's dividend yield for the trailing twelve months is around 2.06%, more than XBI's 0.34% yield.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
PPH VanEck Vectors Pharmaceutical ETF | 2.06% | 1.78% | 1.98% | 2.09% | 1.55% | 1.62% | 1.66% | 1.77% | 1.97% | 1.92% | 2.43% | 1.93% |
XBI SPDR S&P Biotech ETF | 0.34% | 0.37% | 0.15% | 0.02% | 0.00% | 0.04% | 0.20% | 0.00% | 0.28% | 0.24% | 0.26% | 0.61% |
Drawdowns
PPH vs. XBI - Drawdown Comparison
The maximum PPH drawdown since its inception was -51.45%, smaller than the maximum XBI drawdown of -63.89%. Use the drawdown chart below to compare losses from any high point for PPH and XBI.
Loading graphics...
Drawdown Indicators
| PPH | XBI | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -51.45% | -63.89% | +12.44% |
Max Drawdown (1Y)Largest decline over 1 year | -10.02% | -13.39% | +3.37% |
Max Drawdown (5Y)Largest decline over 5 years | -20.26% | -55.04% | +34.78% |
Max Drawdown (10Y)Largest decline over 10 years | -29.70% | -63.89% | +34.19% |
Current DrawdownCurrent decline from peak | -5.56% | -25.70% | +20.14% |
Average DrawdownAverage peak-to-trough decline | -17.38% | -20.91% | +3.53% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 3.88% | 3.65% | +0.23% |
Volatility
PPH vs. XBI - Volatility Comparison
The current volatility for VanEck Vectors Pharmaceutical ETF (PPH) is 5.24%, while SPDR S&P Biotech ETF (XBI) has a volatility of 11.31%. This indicates that PPH experiences smaller price fluctuations and is considered to be less risky than XBI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| PPH | XBI | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 5.24% | 11.31% | -6.07% |
Volatility (6M)Calculated over the trailing 6-month period | 12.00% | 19.25% | -7.25% |
Volatility (1Y)Calculated over the trailing 1-year period | 19.72% | 28.95% | -9.23% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 14.87% | 32.23% | -17.36% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 16.95% | 32.15% | -15.20% |